Evidence for efficacy is based on the results from the VERITAC-2 study
Home World News FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer
Evidence for efficacy is based on the results from the VERITAC-2 study
